RTW Funds disclose 13.3M shares in Tango Therapeutics (NASDAQ: TNGX)

Rhea-AI Filing Summary

Tango Therapeutics disclosure: RTW Investments, LP and Roderick Wong report shared beneficial ownership of 13,300,620 shares of Tango Therapeutics common stock, representing 9.3% of the class based on 142,688,851 shares outstanding as of February 26, 2026. The shares are held by RTW Funds and voting/dispositive power is shared; sole voting and sole dispositive power are reported as zero. The statement is filed on behalf of RTW Investments and Dr. Wong and is signed by Dr. Wong on May 15, 2026.

Key Figures

Shares beneficially owned: 13,300,620 shares Percent of class: 9.3% Shares outstanding (used): 142,688,851 shares +1 more

4 metrics

Shares beneficially owned 13,300,620 shares RTW Investments and Roderick Wong reported amount

Percent of class 9.3% Based on 142,688,851 shares outstanding as of February 26, 2026

Shares outstanding (used) 142,688,851 shares Company figure used for percent calculation as of February 26, 2026

Signature date May 15, 2026 Filing signed by Roderick Wong

Key Terms

Schedule 13G, Shared Dispositive Power, Beneficially owned

3 terms

Schedule 13G regulatory

"This statement is filed by: RTW Investments, LP ..."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Shared Dispositive Power financial

"Shared Dispositive Power 13,300,620.00"

Beneficially owned financial

"Amount beneficially owned: The information required by Item 4(a) is set forth"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Tango Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

87583X109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

RTW Investments, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,300,620.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,300,620.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,300,620.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.3 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Roderick Wong

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,300,620.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,300,620.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,300,620.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.3 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tango Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 201 Brookline Ave., Suite 901, Boston, MA, 02215.
Item 2.
(a)	Name of person filing: This statement is filed by: (i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership and the investment adviser to certain funds (the "RTW Funds"), with respect to shares of Common Stock, par value $0.001 per share (the "Shares") of Tango Therapeutics, Inc. (the "Company") directly held by the RTW Funds; and (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.
(c)	Citizenship: RTW Investments is a Delaware limited partnership. Dr. Wong is a citizen of the United States.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 87583X109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Rows 5 - 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentages set forth in Row 11 of the cover pages are calculated based upon 142,688,851 Shares outstanding as of February 26, 2026 as reported in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2026.
(b)	Percent of class: RTW Investments: 9.3% Dr. Wong: 9.3%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: RTW Investments: 0 Dr. Wong: 0
	(ii) Shared power to vote or to direct the vote: RTW Investments: 13,300,620 Shares Dr. Wong: 13,300,620 Shares
	(iii) Sole power to dispose or to direct the disposition of: RTW Investments: 0 Dr. Wong: 0
	(iv) Shared power to dispose or to direct the disposition of: RTW Investments: 13,300,620 Shares Dr. Wong: 13,300,620 Shares
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2. The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

RTW Investments, LP

Signature:	/s/ Roderick Wong, M.D.
Name/Title:	Roderick Wong, M.D., Managing Partner
Date:	05/15/2026

Roderick Wong

Signature:	s/ Roderick Wong, M.D.
Name/Title:	Roderick Wong, M.D.
Date:	05/15/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement

FAQ

What stake does RTW Investments hold in Tango Therapeutics (TNGX)?

RTW Investments and Roderick Wong each report beneficial ownership of 13,300,620 shares, equal to 9.3% of the class based on 142,688,851 shares outstanding as of February 26, 2026. The shares are held by the RTW Funds.

Does RTW Investments have sole voting or dispositive power over the shares?

No. The filing reports 0 shares of sole voting power and 0 shares of sole dispositive power. Both voting and dispositive powers are reported as shared for 13,300,620 shares by the reporting persons.

On whose behalf were the shares reported in the Schedule 13G filed by RTW?

The shares are reported on behalf of the RTW Funds. The filing states the RTW Funds have the right to receive dividends or proceeds from sale of the reported shares and that the statement is filed by RTW Investments and Dr. Wong.

What dates are relevant in the Schedule 13G filing for TNGX?

Shares outstanding used for the percent calculation: February 26, 2026. Filing signature date: May 15, 2026. These dates anchor the ownership percentage and the filing execution.

Does the Schedule 13G indicate the shares are beneficially owned by Dr. Wong personally?

The filing attributes the shares to RTW Investments and the RTW Funds. Dr. Wong is listed as Managing Partner and files with respect to the RTW Funds' holdings; the statement disclaims that filing alone should be construed as personal beneficial ownership.